Inulin ( DrugBank: Inulin )

4 diseases

ID	Disease name (Link within this page)	Number of trials
6	Parkinson disease	1
96	Crohn disease	1
156	Rett syndrome	1
299	Cystic fibrosis	1

6. Parkinson disease

Clinical trials : 2,307 / Drugs : 2,007 - (DrugBank : 349) / Drug target genes : 188 - Drug target pathways : 199

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-jRCTs041220054	15/08/2022	15/08/2022	The effects of prebiotics on Parkinson's disease patients with wearing-off	The effects of prebiotics on wearing-off and intestinal environment in patients with Parkinson's disease	Parkinson's disease patients with wearing-off over 20 years old	administration of kestose and inulin Dose / Usage) Kestose: 6 g (3 g in the morning, 3 g in the evening) / 2 times a day, orally Inulin: 6g (3g in the morning, 3g in the evening) / 2 times a day, orally Administration period) 8 weeks	Hirooka Yoshiki	Watanabe Hirohisa	Recruiting	>= 20age old	Not applicable	Both	20	Phase 1-2	Japan

Clinical trials : 2,442 / Drugs : 1,278 - (DrugBank : 248) / Drug target genes : 142 - Drug target pathways : 209

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01487759 (ClinicalTrials.gov)	March 2008	6/12/2011	Prebiotic Effect on Metabolites in Crohn's Disease	Metabolite Profiling of the Impact of Oligofructose Enriched Inulin in Crohn's Disease Patients	Crohn Disease	Dietary Supplement: Oligofructose enriched inulin;Dietary Supplement: Maltodextrin	Katholieke Universiteit Leuven	NULL	Completed	18 Years	N/A	Both	67	N/A	Belgium

Clinical trials : 44 / Drugs : 61 - (DrugBank : 23) / Drug target genes : 57 - Drug target pathways : 83

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05420805 (ClinicalTrials.gov)	April 1, 2022	13/6/2022	Protective Role of Pre-/ Post-biotics on Gut Inflammation, Dysbiosis, and Life Quality in Rett Syndrome (Biotics_RTT)	Protective Effects of Pre- and Post-biotics on Gut Inflammation, Microbiota Diversity, Epileptogenesis, and Quality of Life in Rett Syndrome	Rett Syndrome;Dysbiosis;Epilepsy;Quality of Life	Dietary Supplement: ALAC, inulin, FOS, and sodium butyrate;Dietary Supplement: Sodium butyrate and zinc oxide	Azienda Ospedaliera Universitaria Senese	Kolfarma s.r.l. - Italy;European Institute of Oncology	Recruiting	3 Years	N/A	Female	30	N/A	Italy

Clinical trials : 1,695 / Drugs : 1,527 - (DrugBank : 268) / Drug target genes : 111 - Drug target pathways : 174

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04118010 (ClinicalTrials.gov)	March 13, 2020	4/10/2019	Vitamin D and Prebiotics for Intestinal Health in Cystic Fibrosis	Vitamin D and Prebiotics for Intestinal Health in Cystic Fibrosis	Cystic Fibrosis;Dysbiosis	Drug: Vitamin D3;Drug: Placebo vitamin D3;Drug: Inulin;Drug: Placebo Inulin	Emory University	NULL	Completed	18 Years	N/A	All	40	Phase 4	United States